Private Label Three-Day Yeast Infection Cream Offered By Taro
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.
You may also be interested in...
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.